PTO/SB/08a/b (07-06) Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
By Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Ungasyone. —

MARSON Mute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	10/625,204		
Filing Date	July 23, 2003		
First Named Inventor	Carl Gustav Figdor		
Art Unit	1648		
Examiner Name	M. S. Horning		
Attorney Docket Number	ALXN-P03-089		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.'	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/MH/		US-2003/0232745-A1	12-18-2003	Olson et al.	


	FOREIGN PATENT DOCUMENTS						
E va		Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initia	niner s*	No.'	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°

\*EX\_MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. \*Applicant's unique citation designation number (optional). \*2 See Kinds Codes of USPTO Petent Documents at <a href="https://www.uspio.gog">www.uspio.gog</a> or MPEP 901.04. \*3 Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precide the serial number of the patent document. \*Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

			NON PATENT LITERATURE DOCUMENTS	
Exa Initia	niņer s	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not dered. Include copy of this form with next communication to applicant.

icant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.



PTO/S8/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	are required to respond to a collection	n of Information unless it contains a valid QMB control number.  Complete if Known
Substitute for form 1449/PTO	Application Number	10/625,204
INFORMATION DISCLOSURE	Filing Date	07/23/03
STATEMENT BY APPLICANT	First Named Inventor	Carl Gustav FIGDOR
##	Art Unit	Not yet assigned
(Use as many sheets as necessary)	Examiner Name	Not yet assigned
Sheet 3 of 3	Attorney Docket Number	89 DIV1

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
МН	к	CURTIS BM et al. "Sequence and expression of a membrane-associated	
5		immunodeficiency virus envelope glycoprotein gp120", Proc. Natl. Acad. Sci. USA 89:8356-8360 (1992).	
	L	TSUNETSUGU-YOKOTA Y et al., "Efficient Virus Transmission from Dendritic Cells to CD4+ T Cells in Response to Antigen Depends on Close	
	4	Contact through Adhesion Molecules", Virology 239:259-268 (1997).	
	м	ZOETEWEIJ JP and BLAUVELT A, "HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells", J. Biomed. Sci. 5:253-259 (1998).	
	N	MANCA F et al., "Dendritic Cells Are Potent Antigen-Presenting Cells for In Vitro Induction of Primary Human CD4+ T-Cell Lines Specific for HIV gp120",	2
	5	Journal of Acquired Immune Deficiency Syndromes 7:15-23 (1994).	
	0	KNIGHT SC and PATTERSON S, *Bone Marrow-Derived Dendritic Cells, Infection with Human Immunodeficiency Virus, and Immunopathology*, Annu. Rev. Immunol. 15:593-615 (1997).	
$\sqrt{}$	Р	GENBANK Accession No. AB015629 including updates of April 17, 1999; April 20, 1999; April 20, 1999 (later time); July 26, 2001; and July 23, 2002.	
<u> </u>	P		

Examiner		Date	09/27/2006
Signature	/Michelle Horning/	Considered	03/21/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.